AG
SAGE

Aperio Group’s Sage Therapeutics SAGE Stock Holding History

Aperio Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$4.62M Buy
53,352
+1,452
+3% +$107K 0.01% 860
2020
Q3 		$3.17M Buy
51,900
+14,550
+39% +$737K 0.01% 907
2020
Q2 		$1.55M Buy
37,350
+14,381
+63% +$522K 0.01% 1221
2020
Q1 		$659K Buy
22,969
+13,640
+146% +$790K ﹤0.01% 1502
2019
Q4 		$674K Buy
9,329
+1,793
+24% +$221K ﹤0.01% 1650
2019
Q3 		$1.06M Buy
7,536
+21
+0.3% +$3.51K ﹤0.01% 1363
2019
Q2 		$1.38M Buy
7,515
+2,030
+37% +$346K 0.01% 1232
2019
Q1 		$873K Buy
5,485
+3,116
+132% +$451K ﹤0.01% 1431
2018
Q4 		$227K Buy
2,369
+87
+4% +$9.96K ﹤0.01% 2082
2018
Q3 		$322K Buy
2,282
+215
+10% +$33.2K ﹤0.01% 1978
2018
Q2 		$324K Buy
+2,067
New +$325K ﹤0.01% 1963

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's SAGE Position: Q4 2020 in Review

Aperio Group increased its Sage Therapeutics (SAGE) stake by 2.8% in Q4 2020, buying an estimated $107K and bringing the position to 53,352 shares worth $4.62M. The position accounts for 0.01% of the portfolio, ranked #860.

Aperio Group first reported a position in SAGE in Q2 2018 and has held it in 11 quarters since. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Aperio Group held 53,352 shares of Sage Therapeutics worth $4.62M as of Q4 2020.
  • Aperio Group bought 1,452 Sage Therapeutics shares in Q4 2020, an estimated $107K.
  • Sage Therapeutics made up 0.01% of Aperio Group's portfolio in Q4 2020, its #860 holding.
  • Aperio Group first reported a position in Sage Therapeutics in Q2 2018 and has held it in 11 quarters since.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.